FORM FDA 483

FDA issues Form 483 with 9 observations to Aurobindo Pharma's USA facility

"At the end of the inspection, a 'Form 483' has been issued with 9 observations. With respect to the mentioned inspection, we have received a letter from USFDA classifying the inspection as 'Official Action Indicated," Aurobindo Pharma said in a filing with stock exchanges.

More in FORM FDA 483

Biocon gets 6 observations from USFDA after inspection of its Bengaluru plant

Biocon is confident of addressing these expeditiously and remains committed to global standards of quality and compliance, the statement added.
Can USFDA all-clear for Duvvada earn Dr Reddy’s stock a rerating?

The new onco-injectables plant, where DRL manufactures Dacogon and Vidaza, contributes $20-30 million to the company’s revenue.
USFDA conducting inspection of Mohali plant: Sun Pharma

Drug major Sun Pharmaceutical Industries Tuesday said the US health regulator is conducting an inspection of its Mohali facility in Punjab.